Riding on positive data, argenx raises $1.1B while Alzheimer's biotech Acumen lands $130M
An immunology player and an Alzheimer’s biotech each have a big boost in cash — a massive $1.1 billion for argenx and $130 million for Acumen Pharmaceuticals — after selling millions of shares.
Argenx $ARGX says it expects to raise $1.1 billion in a mixed public and private global offering, including 1.5 million shares of American Depository Shares sold for $490 each and 663,918 ordinary shares for €436.37 each in a private placement in Europe and the UK.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
